Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the EBITDA margin high or low?
The EBITDA margin of -18836.70% is 474% below its 4-year average of -3279.44%, around the middle of its 4-year range (-48429.94%–51.62%).
16.52% below its 12-month average of -16166.59%.
Reported quarterly EBITDA margin; no daily interpolation. Q2 FY2026 (2026-06-30): -2241.82%.
EBITDA MARGIN
-18836.70%
EBITDA MARGIN AVG TTM
-16166.59%
EBITDA MARGIN AVG 3Y
-3543.03%
EBITDA MARGIN AVG 5Y
-3279.44%
EBITDA MARGIN AVG 10Y
N/A
EBITDA MARGIN AVG 15Y
N/A
EBITDA MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
-16.52%
CURRENT VS 3Y AVG
-431.65%
CURRENT VS 5Y AVG
-474.39%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
HCW Biologics Inc.
Market Cap
$542320.00
EBITDA Margin
-18836.70%
TTM Avg
-16166.59%
3Y Avg
-3543.03%
5Y Avg
-3279.44%
Market Cap
$388862.00
EBITDA Margin
-2196.68%
TTM Avg
-1727.24%
3Y Avg
-1664.72%
5Y Avg
-2055.32%
Market Cap
$825702.00
EBITDA Margin
-3618.46%
TTM Avg
-3618.46%
3Y Avg
-3618.46%
5Y Avg
-3618.46%
Market Cap
$840509.00
EBITDA Margin
-148.44%
TTM Avg
-191.64%
3Y Avg
-1422.24%
5Y Avg
-1921.61%
Market Cap
$874595.00
EBITDA Margin
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$861915.00
EBITDA Margin
1710.10%
TTM Avg
8440.35%
3Y Avg
4905.18%
5Y Avg
4832.78%
Market Cap
$1.02M
EBITDA Margin
-182712.72%
TTM Avg
-182712.72%
3Y Avg
-182712.72%
5Y Avg
-182712.72%
| NAME | MARKET CAP | EBITDA MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| HCW Biologics Inc. (HCWB) | $542320.00 | -18836.70% | -16166.59% | -3543.03% | -3279.44% |
| CDT Equity Inc. (CDT)vs › | $681478.00 | N/A | N/A | N/A | N/A |
| Niki BioSolutions, Inc. (NIKI)vs › | $388862.00 | -2196.68% | -1727.24% | -1664.72% | -2055.32% |
| Bluejay Diagnostics, Inc. (BJDX)vs › | $825702.00 | -3618.46% | -3618.46% | -3618.46% | -3618.46% |
| Decoy Therapeutics Inc. (DCOY)vs › | $840509.00 | -148.44% | -191.64% | -1422.24% | -1921.61% |
| Bone Biologics Corporation (BBLG)vs › | $874595.00 | N/A | N/A | N/A | N/A |
| GlucoTrack, Inc. (GCTK)vs › | $861915.00 | 1710.10% | 8440.35% | 4905.18% | 4832.78% |
| Aspire Biopharma Holdings, Inc. (ASBP)vs › | $1.02M | -182712.72% | -182712.72% | -182712.72% | -182712.72% |
| Clearmind Medicine Inc. (CMND)vs › | $1.06M | N/A | N/A | N/A | N/A |
| Akanda Corp. (AKAN)vs › | $61301.00 | -1762.94% | -1134.94% | -792.43% | -12891.91% |
Gross Margin
20.0%
EBITDA Margin
-18836.7%
Operating Margin
-20757.7%
Net Margin
-73.2%
Formula: EBITDA Margin = (EBITDA / Revenue) × 100
Why EBITDA Margin matters:
EBITDA Margin = EBITDA / Revenue
EBITDA margin measures operating profitability before interest, taxes, depreciation, and amortization as a percentage of revenue.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EBITDA MARGIN |
|---|---|
| 2026-06-30 | -2241.82% |
| 2026-03-31 | 51.62% |
| 2025-12-31 | -10331.24% |
| 2025-09-30 | -19881.58% |
| 2025-06-30 | -48429.94% |
| 2025-03-31 | -30538.84% |
| 2024-12-31 | -627.46% |
| 2024-09-30 | -835.27% |
| 2024-06-30 | -2424.82% |
| 2024-03-31 | -643.48% |
| 2023-12-31 | -798.04% |
| 2023-09-30 | -562.70% |
| 2023-06-30 | -678.57% |
| 2023-03-31 | -12085.39% |
| 2022-12-31 | -402.98% |
| 2022-09-30 | -213.12% |
| 2022-06-30 | -740.42% |
| 2022-03-31 | -55.75% |
| 2020-12-31 | 54.27% |
